--------------------------------------------------------------------------------

Raxar (grepafloxacin)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved November 1997

Specific Treatments:

chronic bronchitis

General Information

Raxar (grepafloxacin) has been approved for mild to moderate cases of acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; for community-acquired pneumonia caused by the same bacteria as well as Mycoplasma pneumoniae; for uncomplicated gonorrhea caused by Neissaria gonorrhoeae; and for nongonococcal urethritis and cervicitis caused by Chlymidia trachomatis.

Raxar tablets are contraindicated in patients with hepatic failure.

Side Effects

Adverse reactions for a multiple-dose regimen of Raxar 600 mg include a 15.8% incidence of nausea, 17.8% of taste perversion, 5.7% of vomiting, 5.4% of dizziness, 4.2% of diarrhea, and 2.2% of constipation.

---------------------------------------------------------------------------------

[ Home | Discussions | Article Archives | Help | Submit your Site]

Copyright 1996 - 2014 by Gelber Associates All Rights Reserved.